Last reviewed · How we verify
BUPRENORPHINE HYDROCHLORIDE
At a glance
| Generic name | BUPRENORPHINE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
Common side effects
- Headache
- Infection
- Asthenia
- Sweating
- Insomnia
- Nausea
- Constipation
- Pain Abdomen
- Chills
- Vomiting
- Vasodilation
- Flu Syndrome
Serious adverse events
- Oral hypoesthesia
- Glossodynia
- Oral mucosal erythema
- Hyperhidrosis
- Signs and symptoms of withdrawal
- Peripheral edema
Key clinical trials
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System (NA)
- Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections (PHASE2)
- Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder
- Open Trial of Technology-Enhanced Behavioral Intervention for Buprenorphine Retention in Pregnant and Postpartum People (EARLY_PHASE1)
- Extended-release Buprenorphine as a Novel Low-dose Induction Strategy (PHASE2)
- Pain Management Teams Using Whole Health to Optimize Function and Safety in Veterans: The TEAMWORK Trial (NA)
- Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |